EREmiel J. T. Rutgers

Emiel J. T. Rutgers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emiel J. T. Rutgers has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study

    by Julia E.C. Van Steenhoven, Anne Kuijer, Paul J. Van Diest, Joost M. Van Gorp, Marieke Straver, Sjoerd G. Elias, Jelle Wesseling, Emiel Rutgers, Johanna N.H. Timmer-Bonte, Peter Nieboer, et al.

    In this study, in estrogen receptor positive (ER+) early stage breast cancer patients who were considered candidates for 70-gene signature (70-GS, “MammaPrint”) use, we compared molecular subtyping (MS) based on the previously validated 80-gene signature (80-GS, “BluePrint”) versus surrogate pathological subtyping (PS). Between 1 January 2013 and 31 December 2015, 595 clinical intermediate risk ER+ early stage breast cancer patients were enrolled. Hormone receptor (HR) and HER2 receptor status were determined by conventional pathology using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Ki67 was assessed in a subset of patients. The overall concordance between PS and MS for luminal type cancers (A and B together) was 98%. The concordance between PS and MS for luminal A and luminal B type cancers based on the Bloom Richardson histological grade (BR) (n = 586) or Ki67 (n = 185) was low: 64% (Kappa 0.20 [95% CI 0.11–0.28]) and 65% (Kappa 0.22 [95% CI 0.062–0.37]), respectively. In this prospective study (NCT02209857) of a selection of ER+ and predominantly HER2− early-stage breast cancer patients, the additional ability of the 80-GS to distinguish between luminal, HER2-type and basal-like cancers was inherently very limited. The distinction of luminal-type tumors into A and B according to Ki67 status or BR grade versus the 70-GS revealed poor concordance.


  • Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping

    by Gordon F. Schwartz, Harry Bartelink, Harold J. Burstein, Blake Cady, Luigi Cataliotti, Ian S. Fentiman, Roland Holland, Kevin S. Hughes, Shahla Masood, Beryl McCormick, et al.

    A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co‐morbidities, but also incorporating steroid hormone and Her‐2‐neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.


  • Open Access

    Adjuvant therapy in stage I carcinoma of the breast

    by Gordon F. Schwartz, Jorge Reis‐Fihlo, Lajos Pusztai, Ian S. Fentiman, Roland Holland, Harry Bartelink, Emiel J. T. Rutgers, Lawrence J. Solin, Juan Palazzo, the Consensus Committee

    BACKGROUND: Breast Health International and the Kimmel Cancer Center of Thomas Jefferson University cosponsored a consensus conference that included an international group of experts. METHODS: Since the adoption of adjuvant chemotherapy for stage I, lymph node‐negative breast cancers in 1988, investigators have tried to “fine‐tune” the treatment criteria. At this consensus conference, the group debated recommendations for adjuvant hormone and cytotoxic chemotherapy in stage I breast cancers. RESULTS: Discussions during the conference addressed issues of adjuvant therapy for stage I breast cancer and the influence of multigene analyses and molecular phenotyping. The panelists discussed various demographic, morphologic, biologic, and genetic factors expressed by individual tumors and their influence on treatment decisions. CONCLUSIONS: The panel tried to create guidelines for the consideration of adjuvant treatment of these patients, including both hormone and cytotoxic regimens. They also encouraged further research into the molecular analysis of breast cancers and the introduction of clinical trials based on current data, although they concluded that it is too early to add any of those analyses into the decision‐making algorithms of recommendations for the treatment of stage I breast cancer. Cancer 2012;. © 2012 American Cancer Society.


  • Open Access

    Breast-conserving therapy for paget disease of the nipple

    by Nina Bijker, Emiel J.T. Rutgers, Luc Duchateau, Johannes L. Peterse, Jean-Pierre Julien, Luigi Cataliotti, EORTC Breast Cancer Cooperative Group

    BACKGROUND The purpose of the current study was to assess the outcome of breast‐conserving therapy by means of a cone excision and radiotherapy in patients with Paget disease of the nipple without associated invasive breast carcinoma. METHODS Between 1987 and 1998, 61 eligible patients were registered in the European Organization for Research and Treatment of Cancer Study 10873. The majority of patients (97%) presented without an associated palpable mass. At histologic examination, the majority (93%%) of patients had an underlying ductal carcinoma in situ (DCIS); in the remaining 7%, only Paget disease was found. Treatment was comprised of a complete excision of the nipple‐areolar complex including the underlying breast tissue with tumor free margins, followed by external irradiation to the whole breast (50 gray in 25 fractions). The primary endpoint was local recurrence. RESULTS At a median follow‐up of 6.4 years, 4 of the 61 patients developed a recurrence in the treated breast (1 patient with DCIS and 3 patients with invasive disease). One patient with an invasive local recurrence died of disseminated breast carcinoma. The 5‐year local recurrence rate was 5.2% (95% confidence interval, 1.8–14.1%). CONCLUSIONS Breast‐conserving therapy is a feasible alternative for patients with Paget disease and a limited extent of underlying DCIS. To achieve good local control, treatment should be comprised of a complete excision of the nipple‐areolar complex including the underlying disease, followed by irradiation to the whole breast. Cancer 2001;91:472–7. © 2001 American Cancer Society.


    • 1 January 2000
      • Vol. 89  (4) , 331-5

    How to do sentinel node biopsy in breast cancer.

    by E J Rutgers, O E Nieweg

  • Open Access

    Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy

    by Nina Bijker, Emiel J. T. Rutgers, Johannes L. Peterse, Joop A. van Dongen, August A. M. Hart, Jacques H. Borger, Bin B. R. Kroon